GSK Got Caught Editing Its Own Paper Trail on a Shingles Vaccine Push
The U.K. drug watchdog called GSK's account of a health agency's involvement "grossly misleading" after the company left out the parts of the record that undercut its story.
GSK initially won its case. Then the U.K. Health Security Agency read what GSK had actually told regulators about their relationship, and the case restarted.
The PMCPA had cleared a GSK video promoting a shingles vaccination program of breaching prescription-medicine advertising rules. UKHSA challenged that outcome, pointing out that GSK's version of events omitted a section of UKHSA's own meeting minutes stating the agency intended to "maintain a professional distance," along with an email in which UKHSA explicitly said it was "not within our remit to give any formal approvals." The panel also found GSK had claimed it "never asserted that UKHSA was providing formal ministerial approval," a claim the fuller record contradicted. The PMCPA called the omissions "grossly misleading" and GSK's lack of transparency "totally unacceptable," issuing a public reprimand.
GSK said it had acted "in good faith" and that "greater information and context could have been provided," apologizing for the gap. That is a careful way of admitting the company shaped its own defense by leaving out the parts that hurt it, an odd strategy in a system where the other party can simply produce the missing documents.
The lesson for anyone building a campaign that leans on a government partnership: the partner's paper trail is not yours to edit, and regulators increasingly know to ask for the whole file, not just the pages a company chooses to submit.
Source: Fierce Pharma
Kyle Duford, Founder & Editor, BRNDWIRE. More from Kyle →
